Last reviewed · How we verify
Quadrivalent influenza virus subunit vaccine
A quadrivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus (two A subtypes and two B lineages).
A quadrivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus (two A subtypes and two B lineages). Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Quadrivalent influenza virus subunit vaccine |
|---|---|
| Sponsor | Ab&B Bio-tech Co., Ltd.JS |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified viral subunits from four circulating influenza strains, which are presented to the immune system to elicit both humoral (antibody) and cellular immune responses. This preparation allows the body to recognize and mount a rapid, protective response upon exposure to wild-type influenza virus, reducing infection risk and disease severity.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site pain, redness, or swelling
- Myalgia (muscle pain)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months (PHASE3)
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
- Efficacy Study With QIVc in Pediatric Subjects (PHASE3)
- Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers (PHASE2, PHASE3)
- Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults (PHASE2)
- Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults (PHASE2)
- Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age (PHASE2)
- A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: